The five-year invasive disease-free survival (iDFS) rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement 1. These ...
In the US alone, more than 10 million adults over age 50 are estimated to have osteoporosis, of whom more than 80% are women. 3 It is predicted that one in two of these women and one in four men will ...
Novartis will continue to provide supply of HCQ for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate, where certain conditions are met and the medicine is used ...
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of ...
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled ...
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC NATALEE ...
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025; DTP offering to expand to other approp ...
ノバルティス ファーマ株式会社(本社:東京都港区、代表取締役社長:ジョンポール・プリシーノ)(以下「ノバルティス ファーマ」)は、本日、「プルヴィクト ® 静注」(一般名 ...
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer ...